CRIS - Curis, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.7511
+0.0041 (+0.55%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.7470
Open0.7411
Bid0.7299 x 500
Ask0.8250 x 2000
Day's Range0.7300 - 0.7947
52 Week Range0.7300 - 5.2000
Volume686,291
Avg. Volume289,685
Market Cap24.871M
Beta (3Y Monthly)0.45
PE Ratio (TTM)N/A
EPS (TTM)-1.0490
Earnings DateMar 6, 2019 - Mar 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • GlobeNewswire9 days ago

    Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswire19 days ago

    Curis to Present at the 60th Annual Meeting of the American Society of Hematology

    LEXINGTON, Mass. , Nov. 20, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, ...

  • PR Newswirelast month

    Curis to Present at 33rd Society for Immunotherapy of Cancer Annual Meeting and Cowen IO NEXT Summit

    LEXINGTON, Mass. , Nov. 7, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, ...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of CRIS earnings conference call or presentation 1-Nov-18 12:30pm GMT

    Q3 2018 Curis Inc Earnings Call

  • Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates
    Zackslast month

    Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates

    Curis (CRIS) delivered earnings and revenue surprises of 29.03% and 19.62%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Curis: 3Q Earnings Snapshot

    On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 22 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

  • PR Newswirelast month

    Curis Reports Third Quarter 2018 Financial Results

    LEXINGTON, Mass., Nov. 1, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2018. "Following Curis's recent leadership change, we are increasing our focus on the clinical execution of our three first-in-class therapeutics that have the potential to be significant and innovative cancer treatments. "To achieve this goal, we are re-allocating resources to prioritize clinical operations and have implemented a reduction in headcount and expenditure on pre-clinical science, pipeline expansion, and general and administrative expenses.

  • PR Newswire2 months ago

    Curis to Release Third Quarter Financial Results and Hold Conference Call on November 1, 2018

    LEXINGTON, Mass., Oct. 23, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter 2018 financial results on Thursday, November 1, 2018, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. ET. Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors.

  • GlobeNewswire2 months ago

    Investor Expectations to Drive Momentum within Ormat Technologies, The Andersons, Freshpet, Curis, Ultra Clean, and Edge Therapeutics — Discovering Underlying Factors of Influence

    NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Curis (CRIS) Shares March Higher, Can It Continue?
    Zacks2 months ago

    Curis (CRIS) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Curis, Inc. (CRIS).

  • Investopedia2 months ago

    Top 3 Healthcare Penny Stocks for 2018

    The healthcare industry can be precarious for stocks of large companies, much less penny stocks. None of these are new companies – they have made progress in developing products and finding the marketing outlets that are needed to sustain them. Because of the higher risk, investors should continuously perform due diligence.

  • PR Newswire2 months ago

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., Oct. 5, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that on October 1, 2018, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 30,000 shares of Curis common stock to a new employee, with a grant date of October 1, 2018 (the "Q4 2018 Inducement Grant"). The Q4 2018 Inducement Grant has an exercise price per share equal to the closing price of the Company's common stock on October 1, 2018. The stock option has a 10 year term and vests over four years, with 25% of the original number of shares underlying the award vesting on the first anniversary of the employee's date of hire and an additional 6.25% of the original number of shares underlying the award vesting on each successive three-month period thereafter, subject to the employee's continued service with the Company through the respective vesting dates.  The stock option was granted as an inducement equity award outside of the Company's Third Amended and Restated 2010 Stock Incentive Plan and was made as an inducement material to the employee's acceptance of employment with the Company.

  • Simply Wall St.2 months ago

    Who Are The Top Investors In Curis Inc (NASDAQ:CRIS)?

    Every investor in Curis Inc (NASDAQ:CRIS) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning Read More...

  • PR Newswire2 months ago

    Curis to Present at the Cantor Fitzgerald Global Healthcare Conference

    James Dentzer, the Company's new President & Chief Executive Officer, will provide a brief overview of the Company's pipeline of drug candidates and business strategy. A live webcast of the presentation will be available by visiting the investor section of Curis' website http://investors.curis.com/events-and-presentations.

  • PR Newswire2 months ago

    Curis Announces Leadership Change

    LEXINGTON, Mass., Sept. 24, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced a change in leadership with the appointment of James E. Dentzer as President and Chief Executive Officer effective immediately. In addition, Mr. Dentzer will become a member of the Curis Board of Directors. Mr. Dentzer, who joined Curis in 2016, was promoted earlier this year to Chief Operating Officer to manage all functions outside of research and development, including business development, manufacturing, quality, human resources, finance, legal, IT, and investor and public relations.

  • PR Newswire3 months ago

    Curis to Present at the Baird 2018 Global Healthcare Conference

    LEXINGTON, Mass., Aug. 28, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will present at the Baird 2018 Global Healthcare Conference on Wednesday, September 5 at 2:35-3:05 PM in Session III - Empire Ballroom B, Mezzanine Level of the InterContinental New York Barclay in New York. The presentation will be held using a fireside-chat format in which Ali Fattaey, Ph.D. President and Chief Executive Officer, will provide a brief overview of the Company's pipeline of drug candidates and business strategy, after which an equity analyst will moderate a question and answer session. A live webcast of the presentation will be available by visiting the investors section of Curis' website http://investors.curis.com/events-and-presentations.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of CRIS earnings conference call or presentation 2-Aug-18 12:30pm GMT

    Q2 2018 Curis Inc Earnings Call

  • Curis (CRIS) Reports Q2 Loss, Lags Revenue Estimates
    Zacks4 months ago

    Curis (CRIS) Reports Q2 Loss, Lags Revenue Estimates

    Curis (CRIS) delivered earnings and revenue surprises of 36.59% and -2.16%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press4 months ago

    Curis: 2Q Earnings Snapshot

    The Lexington, Massachusetts-based company said it had a loss of 26 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • PR Newswire4 months ago

    Curis Reports Second Quarter 2018 Financial Results

    -- Management to host conference call today at 8:30 a.m. EDT -- LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization ...

  • PR Newswire4 months ago

    Curis to Release Second Quarter Financial Results and Hold Conference Call on August 2, 2018

    LEXINGTON, Mass., July 27, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2018 financial results on Thursday, August 2, 2018, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT. Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the PDL1/VISTA antagonist CA-170, and the PDL1/TIM3 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas, and in a Phase 2 trial in India conducted by Aurigene.

  • Investopedia5 months ago

    Top 3 Healthcare Penny Stocks for 2018

    The healthcare industry can be precarious for stocks of large companies, much less penny stocks. Of course, small-cap healthcare companies can be nudged out of the market by big competitors, and they can simply become unable to service debt when products and services don't sell quickly enough. None of these are new companies – they have made progress in developing products and finding the marketing outlets that are needed to sustain them.

  • PR Newswire5 months ago

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., July 9, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that on July 2, 2018, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 12,000 shares of Curis common stock to a new employee, with a grant date of July 2, 2018 (the "Q3 2018 Inducement Grant"). Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors.  Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology.  As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the PDL1/VISTA antagonist CA-170, and the PDL1/TIM3 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948.  CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas, and in a Phase 2 trial in India conducted by Aurigene.  CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma.  Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.